<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/235118-novel-peptides-the-preparation-and-a-medicament-comprising-the-same by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 14:37:14 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 235118:NOVEL PEPTIDES, THE PREPARATION AND A MEDICAMENT COMPRISING THE SAME</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">NOVEL PEPTIDES, THE PREPARATION AND A MEDICAMENT COMPRISING THE SAME</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>ABSTRACT NOVEL PEPTIDES, THE PREPARATION AND A MEDICAMENT COMPRISING THE SAME 2240/MAS/96 Novel compounds of the formula R1R2N-CHX-CO-A-B-D-E-(G)S-K in which R1, R2, A, B, D, E, G, K, x, and s have the meanings sta¬ted in the description, and the preparation thereof are descri¬bed. The novel compounds have an antineoplastic effect.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td> <br><br>
Novel peptides, the preparation and use thereof Description<br>
I<br>
The invention described herein provides novel peptides and deriv¬atives thereof which offer potentially improved therapeutic uti¬lities for the treatment of neoplastic diseases as compared to dolastatin -10 and -15 (U.S. Patent Nos. 4,879,276 and 4,816,444) \  and the compounds described in WO 93/23424.<br>
Compounds of this invention include novel peptides of the for¬mula I<br>
RlR2N-CHX-CO-A-B-D-E-(G)S-K      I<br>
where<br>
R1      is hydrogen, methyl, or ethyl;<br>
R2      is methyl; or ethyl; or<br>
R1-N-R2  together are a pyrrolidine ring;<br>
A      is a valyl, isoleucyl, allo-isoleucyl, 2-tert-butylgly-cyl, 2-ethylglycyl, norleucyl or norvalyl residue;<br>
B      is a N-methyl-valyl, N-methyl-norvalyl, N-methyl-leucyl, N-methyl-isoleucyl, N-methyl-2-tert-butylglycyl, N-methyl-2-ethylglycyl, or N-methyl-norleucyl residue,-<br>
D      is a prolyl, homoprolyl, hydroxyprolyl, or thiazoli-dine-4-carbonyl residue;<br>
E      is a prolyl, homoprolyl, hydroxyprolyl, thiazolidine-4-<br>
carbonyl, trans-4-fluoro-L-prolyl, cis-4-fluoro-L-prolyl, trans-4-chloro-L-prolyl or cis-4-chloro-L-prolyl residue;<br>
X      is ethyl, propyl, butyl, isopropyl, sec. butyl, tert.-butyl, cyclopropyl, or cyclopentyl;<br>
G      is a L-2-tert.butylglycyl, D-2-tert.butylglycyl, D-valyl, D-isoleucyl, D-leucyl, D-norvalyl, l-aminopentyl~l-carbonyl, or 2,2-dimethylglycyl residue;<br><br><br><br>
-N(CH3) OCH2CH2CH3 ,    -N (CH3) OCH (CH3) 2 -    -N{CH3) 0 (CH2) 3CH3, -N(CH3)OCH2C6H5,    -NH(CH2)2C6H5,    -NH<ch2></ch2>
-NHCH[CH(CH3)2]2,    -NHC{CH3)2CN,    -NHCH(CH3) CH (OH) C6HS,    -NHCH2-cyclo-hexyl,    -NHCH2C(CH3)3,    -NHCH2CH{CH3) 2,    -N(CH3)2,    -N(CH2CH3)2, -N(CH2CH2CH3)2,    -NHCH2CF3,    -HHCH(CH2F) 2,   -NHCH2CH2F,    -NHCH2CH2OCH3, -NHCH2CH2SCH3,    -NHCH2CHCH2,    -NH-C (CH3)2CH=CH2,    -NHC (CH3) 2C= CH, -NHC(CH2CH3)2C2£CH,    -NHC (CH3) 2CH2CH2OH,    -NH(CH2CH20) 2CH2CH3, -NHC(CH3)2CH(CH3)2,    -NHC (CH3) 2CH2CH2CH3,    -NHC (CH3) 2CH2C6H5, -N(OCH3)CH(CH3)2,    -N{OCH3)CH2CH3,    -N (OCH3)CH2CH2CH3, -N(OCH3)CH2C6H5,    -N(OCH3)C6H5,    -N{CH3)OC6H5,    -NHCH [CH (CH3) 2] 2, -N (OCH3) CH2CH2CH2CH3, or the special ring systems mentioned above.<br>
. Preferred are compounds of  the formula I where the substituents R1,   R2,   A,   B,   D,   E,   X,   G and s have  the following meanings:<br>
R1	hydrogen,  methyl,  or ethyl,   especially methyl;<br>
) R2	methyl or ethyl,   especially methyl;<br>
A	valyl,   isoleucyl,   2-tert-butylglycyl,   2-ethylglycyl,  nor-<br>
leucyl or norvalyl,   especially valyl,   isoleucyl,   2-tert-butylglycyl ,  2-ethylglycyl,<br>
B	N-methyl-valyl,  N-methyl-norvalyl,  N-methyl-isoleucyl,<br>
N-methyl-2-tert-butylglycyl, N-methyl-2-ethylglycyl, or N-methyl-norleucyl,   especially N-methyl-valyl, N-methyl-2-ethylglycyl,   N-methyl-norleucyl,   N-methyl-isoleucyl,  or N-methyl-2-tert.butyl-glycyl;<br>
D	prolyl,   homoprolyl or thiazolidine-4-carbonyl,   especially<br>
prolyl or thiazolidine-4-carbonyl;<br>
E	prolyl,  homoprolyl,   thiazolidine-4-carbonyl,<br>
trans-4-fluoro-L-prolyl,  cis-4-fluoro-L-prolyl, trans-4-chloro-L-prolyl or cis-4-chloro-L-prolyl, especially prolyl,   trans-4-fluoro-prolyl,   cis-4-fluoro-prolyl,   trans-4-chloro-prolyl,  or cis-4-chloro-prolyl;<br>
X	ethyl,  propyl,   isopropyl,   sec.butyl,   tert.butyl or cyclo-<br>
propyl,   especially ethyl,   isopropyl,   sec.butyl or tert.butyl;<br>
G	L-2-tert.butylglycyl,   D-2-tert.butylglycyl,   D-valyl,<br>
D-isoleucyl,  D-leucyl or 2,2-dimethylglycyl residue;<br><br><br><br><br><br><br>
2c This invention also provides methods for preparing the compounds of formula I, pharmaceutical compositions containing such compounds together with a pharmaceutical^ acceptable carrier and methods for using same for treating cancer in mammals.<br>
2f5  The new compounds may be present as salts with physiologically tolerated acids such as: hydrochloric acid, citric acid, tartaric acid, lactic acid, phosphoric acid, methanesulfonic acid, acetic acid, formic acid, maleic acid, fumaric acid, malic acid, suc¬cinic acid, malonic acid, sulfuric acid, L-glutamic acid, L-as-<br>
3Ql partic acid, pyruvic acid, mucic acid, benzoic acid, glucuronic acid, oxalic acid, ascorbic acid and acetylglycine.<br>
The novel compounds can be prepared by known methods of peptide chemistry. Thus, the peptides can be assembled sequentially from<br>
36 amino acids or by linking suitable small peptide fragments. In the sequential assemblage, starting at the C terminus the peptide chain is extended stepwise by one amino acid each time. In frag¬ment coupling it is possible to link together fragments of dif¬ferent lengths, and the fragments in turn can be obtained by se-<br>
4ft quential assemblage from amino acids or themselves by fragment-coupling.<br>
Both in the sequential assemblage and in the fragment coupling it is necessary to link the units by forming an amide linkage. Enzy-?5 matic and chemical methods are suitable for this.<br><br>
Chemical methods for forming the amide linkage are described'in detail by Mueller, Hethoden der organischen Chemie Vol. XV/2, pp 1 to 364, Thieme Verlag, Stuttgart, 1974; Stewart, Young, Solid Phase Peptide Synthesis, pp 31 to 34, 71 to 82, Pierce Chemical \  Company, Rockford, 1984; Bodanszky, Klausner, Ondetti, Peptide Synthesis, pp 85 to 128, John Wiley &amp; Sons, New York, 1976; The Practice of Peptide Synthesis, M. Bodanszky, A. Bodanszky, Springer-Verlag, 1994, and other standard works on peptide chemistry. Particular preference is given to the azide method, i the symmetric and mixed anhydride method, in situ generated or preformed active esters, the use of urethane protected N-carboxy anhydrides of amino acids and the formation of the amide linkage using coupling reagents, especially dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (Die ), l-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), pivaloylchloride, l-ethyl-3-(3-dimethylaminopropyDcarbodiimide hydrochloride (EDCI) , n-propan-ephosphonic anhydride (PPA), N,N-bis(2-oxo-3-oxazolodinyl)-amido-phosphoryl chloride (B0P-C1), bromo-tris-pyrrolidinophosphonium hexafluorophosphate (PyBrop), diphenylphosphoryl azide (DPPA), ) Castro's reagent (BOP, PyBop), 0-benzotriazolyl-N,N,N',N'-tetra-methyluronium salts (HBTU), 0-azabenzotriazolyl-N,N,N',N'-tetra-methyluronium salts (HATU), diethylphosphoryl cyanide (DEPCN), 2, 5-diphenyl-2,3-dihydro-3-oxo-4-hydroxythiophene dioxide (Steglich's reagent; KOTDO) and l,l'-carbonyldiimidazole (CDI). i The coupling reagents can be employed alone or in combination with additives such as N,N-dimethyl-4-aminopyridine (DMAP), N-hydroxy-benzotriazole (HOBt), N-hydroxybenzotriazine (HOOBt), Azabenzotriazole, N-hydroxysuccinimide (HOSu) or 2-hydroxypyri-dine. i Whereas it is normally possible to dispense with protective groups in enzymatic peptide synthesis, reversible protection of reactive groups not involved in formation of the amide linkage is necessary for both reactants in chemical synthesis. Three conven¬tional protective group techniques are preferred for the chemical peptide synthesis: the benzyloxycarbonyl (Z), the t-butoxycarbo-nyl (Boc) and the 9-fluorenylmethoxycarbonyl (Fmoc) techniques.<br>
Identified in each case is the protective group on the alpha-amino group of the chain-extending unit. A detailed reviev of amino-acid protective groups is given by Mueller, Methodefi der organischen Chemie Vol. XV/1, pp 20 to 906, Thieme Verlag, Stutt¬gart, 1974. The units employed for assembling the peptide chain can be reacted in solution, in suspension or by a method similar to that described by Merrifield in J. Amer. Chem. Soc. 85 (1963) f  2149.<br><br>
Suitable for peptide synthesis in solution are all solvents which are inert under the reaction conditions, especially water, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), acetonitrile, dichloromethane (DCM), ethyl acetate, 1,4-dioxane, tetrahydro-I furan (THF), N-methyl-2-pyrrolidone (KMP) and mixtures of the said solvents.<br>
Peptide synthesis on the polymeric support can be carried out in all inert organic solvents in which the amino-acid derivatives<br>
I used are soluble. However, preferred solvents additionally have resin-swelling properties, such as DMF, DCM, NMP, acetonitrile and DMSO, and mixtures of these solvents. After synthesis is complete, the peptide is cleaved off the polymeric support. The conditions under which cleavage off the various resin types is<br>
■ possible are disclosed in the literature. The cleavage reactions most commonly used are acid- and palladium-catalyzed, especially cleavage in liquid anhydrous hydrogen fluoride, in anhydrous tri-fluoromethanesulfonic acid, in dilute or concentrated trifluor'o-acetic acid, palladium-catalyzed cleavage in THF or THF-DCM mixtures in the presence of a weak base such as morpholine or cleavage in acetic acid/dichloromethane/trifluoroethanol mix¬tures. Depending on the chosen protective groups, these may be retained or likewise cleaved off under the cleavage conditions.<br>
Partial deprotection of the peptide may also be worthwhile when certain derivatization reactions are to be carried out.<br>
Peptides dialkylated at the N-terminus can be prepared either by coupling on the appropriate N,N-di-alkylamino acids in solution or on the polymeric support, by reductive alkylation of the res¬in-bound peptide in DMF/1% acetic acid with NaCNBH3 and the ap¬propriate aldehydes, by hydrogenation of the peptide in solution in the presence of aldehyde or ketone and Pd/C.<br>
The various non-naturally occurring amino acids as well as the various non-amino acid moieties disclosed herein may be obtained from commercial sources or synthesized from commercially-avail¬able materials using methods known in the art. For example, amino acids building blocks with R1 and R2 moieties can be prepared ac¬cording to E. Wuensch, Houben Weyl, Meth. d. Org. Chemie, Bd. XV, 1, p. 306 following, Thieme Verlag Stuttgart 1974 and Literature cited therein.<br>
The compounds of this invention may be used to inhibit or other-<br>
 wiss treat solid tumors (e.g. tumors of the lung, breast, colon,<br>
prostate, bladder, rectum, or endometrial tumors) or hematologi-<br><br>
cal malignancies (e.g. leuksmias, lymphomas) by administration of the compound to the mammal.<br>
It is a special advantage of the new compounds that they are very j  resistant to enzymatic degradation and can also be administered orally.<br>
Administration may be by any of the means which are conventional for pharmaceutical, preferably oncological, agents, including ) oral and parenteral means such as subcutaneously, intravenously, intramuscularly and intraperitoneally.<br>
The compounds may be administered alone or in the form of pharma¬ceutical compositions containing a compound of formula I together i with a pharmaceutically accepted carrier appropriate for the de¬sired route of administration. Such pharmaceutical compositions may be combination products, i.e., may also contain other thera¬peutically active ingredients.<br>
i The dosage to be administered to the mammal will contain an ef¬fective tumor-inhibiting amount of active ingredient which will depend upon conventional factors including the biological activ¬ity of the particular compound employed; the means of administra¬tion; the age, health and body weight of the recipient; the na¬ture and extent of the symptoms; the frequency of treatment; the administration of other therapies; and the effect desired, A typ¬ical daily dose will be about 0.05 to 50 milligrams per kilogram of body weight on oral administration and about 0.01 to 20 milli¬grams per kilogram of body weight on parenteral administration.<br>
The novel compounds can be administered in conventional solid or liquid pharmaceutical administration forms, e.g. uncoated or (film-)coated tablets, capsules, powders, granules, suppositories or solutions. These are produced in a conventional manner. The active substances can for this purpose be processed with conven¬tional pharmaceutical aids such as tablet binders, fillers, pre¬servatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, sustained re¬lease compositions, antioxidants and/or propellant gases (cf. H. Sucker et al.: Pharmazeutische Technologie, Thieme-Verlag, Stutt¬gart, 1978). The administration forms obtained in this way nor¬mally contain 1-90% by weight of the active substance.<br>
The following examples are intended to illustrate the invention. The proteinogenous amino acids are abbreviated in the examples using the known three-letter code. Other abbreviations used: Me2Val = N,N-dimethylvaline, MeVal = N-methylvaline.<br><br>
I.  The peptides claimed in claim 1 are either synthesized by-classical solution synthesis using standard Z- and Boc-methodology as described above or by standard methods of solid-phase synthesis using Boc and Fmoc protective group techniques.<br>
In the case of solid phase synthesis, the N,N-dialkyl-penta- or hexapeptide acids are liberated from the solid support and further coupled with the corresponding C-ter-minal amines in solution. B0P-C1 and PyBrop were used as reagents for coupling of the amino acid following the N-methylamino acids. The reaction times were correspond¬ingly increased. For reductive alkylation of the N-termi-nus, the peptide-resin was deprotected at the N terminus and then reacted with a 3-fold molar excess of aldehyde or ketone in DMF/1% acetic acid with addition of 3 equiv¬alents of NaCNBH3. After the reaction was complete (nega¬tive Kaisertest) the resin was washed several times with water, isopropanol, DMF and dichloromethane.<br>
In solution synthesis, the use of either Boc-protected amino acid NCAs (N-tert.-butyloxycarbonyl-amino cicid-N-carboxy-anhydrides), Z-protected amino acid NCAs (N-ben-zyloxycarbonyl-amino acid-N-carboxy-anhydrides), or the use of pivaloylchloride as condensing agent respectively is most advantageous for coupling of the amino acid fol¬lowing the N-methylamino acids. Reductive alkylation of the N terminus can e.g. be achieved by reaction of the N-terminally deprotected peptides or amino acids with the corresponding aldehydes or ketones using NaCNBH3 or hy¬drogen, Pd/C.<br>
. Purification and characterization of the peptides<br>
Purification was carried out by gel chromatography (SEPHADEX G-10, G-15/10% HOAc, SEPHADEX LH20/MeOH), me¬dium pressure chromatography (stationary phase: HD-SIL C-18, 20-45 mikron, 100 Angstrom; mobile phase: gradient with A = 0.1% TFA/ MeOH, B = 0.1% TFA/water), or prepara¬tive HPLC (stationary phase: waters Delta-Pak C-18, 15 mikron, 100 Angstrom; mobile phase: gradient with A = 0,1 % TFA/MeOH, B = 0.1 % TFA/water).<br><br>
1*<br>
The purity of the resulting products was determined by analytical HPLC (stationary phase: 100 2.1 mm VYDAC C-18, 5 1, 300 A; mobile phase: acetonitrile-water gradient, buffered with 0.1% TFA, 40°C). 1<br>
Characterization was by amino-acid analysis and fast atom bombardment mass spectroscopy.<br>
B.  Specific procedures<br>
EXAMPLE 1  (SEQ ID NO: 1)<br>
Me2Val-Val-MeVal-Pro-Pro-NHCH(CH3)2 a)  Z-MeVal-Pro-OMe<br>
66.25 g {250 mmol) z-MeVal-OH were dissolved in 250 ml dry dichloromethane. After addition of 35.41 ml {262.5 mmol&gt; triethylamine, the reaction mixture was cooled to -25° C and 32.27 ml (262.5 mmol) pivaloyl chloride were added. After stirring for 2,5 h, 41.89 g (250 mmol) H-Pro-OMe x HC1 in 250 ml dichloromethane, neutralized with 36.41 ml (262.5 mmol) triethylamine at 0°C, were added to the reaction mixture. 'Stirring continued for 2 h at -25° C and overnight at room temperature. The reaction mixture was diluted with dichloro¬methane and thoroughly washed with saturated aqueous NaHCC&gt;3 solution (3x), water (lx), 5 % citric acid (3x) and saturated NaCl solution. The organic phase was dried over sodium sul¬fate and evaporated to dryness. The residue (91.24 g) was stirred with petroleum ether overnight and filtered. 62.3 g of product were obtained.<br>
b)	H-MeVal-Pro-OMe<br>
48.9 g (130 mmol) Z-MeVal-Pro-OMe were dissolved in 490 ml methanol. After addition of 10.9 ml (130 mmol) concentrated hydrochloric acid and 2.43 g  10 % Palladium/charcoal, the reaction mixture was hydrogenated. Filtration and evaporation to dryness yielded 36.43 g of the product.<br>
c)	Z-Val-MeVal-Pro-OMe<br>
18.1 g (65 mmol) H-MeVal-Pro-OMe, 21.6 g (78 mmol) Z-Val-N-carboxyanhydride and 22.8 ml {130 mmol) diisopropylethyla-mine were stirred in 110 ml DMF at 40° C for 2 d. After evap¬oration of DMF, dichloromethane was added and the organic phase washed with saturated aqueous KaHC03 solution (3x),<br><br>
water (lx), 5 % citric acid (3x) and saturated NaCl solution. The organic phase was dried over sodium sulfate and evapo¬rated to dryness. The product (29.3 g) was obtained as a vis- ■ cous oil.<br><br>
29.3 g (61.6 mmol) of 2-Val-MeVal-Pro-OMe were dissolved in 230 ml methanol. After addition of 1.15 g 10 % Palladium/ charcoal, the reaction mixture was hydrogenated. Filtration and evaporation to dryness yielded 21.96 g of the product.<br>
Z-Val-Val-MeVal-Pro-OMe<br>
15.29 g (61 mmol) Z-Val-OH and 21.96 g (61 mmol) H-Val-MeVal-Pro-OMe were dissolved in 610 ml dichloromethane and cooled to 0°C. After addition of 8.16 ml (73.2 mmol) N-Methylmorpho-line, 2.77 g (20.3 mmol) HOBt and 11.74 g (61 mmol) EDCI, the reaction mixture was stirred overnight at room temperature, diluted with dichloromethane and thoroughly washed with satu¬rated aqueous NaHCO3 solution (3x), water (lx), 5 % citric acid (3x) and saturated NaCl solution. The organic phase was dried over sodium sulfate and evaporated to dryness to yield 31.96 g of the product.<br>
z-val-val-Meval-Pro-OH<br>
31.96 g (57 mmol) Z-Val-Val-MeVal-Pro-OMe were dissolved in 250 ml methanol. 102.6 ml of a 1 N LiOH solution was added and the mixture stirred overnight at room temperature. After addition of 500 ml water, the aqueous phase was washed three times with ethyl acetate, adjusted to pH 2 at 0° C and ex¬tracted three times with ethyl acetate. The organic phase was dried over sodium sulfate and evaporated to dryness yielding 30.62 g of the desired product as a white solid.<br>
Z-Val-Val-Meval-Pro-Pro-NHCH(CH3) 2<br>
2 g (3.35 mmol) Z-Val-Val-MeVal-Pro-OH and 0.664 g (3.35 mmol) H-Pro-NHCH(CH3)2 were dissolved in 34 ml of dry dichloromethane. After cooling to 0°C, 1.35 ml (12.1 mmol) N-methylmorpholine, 0.114 g (0.84 mmol) HOBt and 0.645 g<br>
(3.35 mmol) EDCI were added and the reaction mixture stirred overnight at room temperature. 80 ml dichloromethane were added and the organic phase thoroughly washed with saturated aqueous NaHC03 solution (3x), water (lx), 5 % citric acid<br>
(3x) and saturated NaCl solution (lx). The organic phase was<br><br>
dried over sodium sulfate and evaporated to dryness to yield 1.96 g of the product which was used in the next reaction without further purification.<br>
h)  Me2Val-Val-MeVal-Pro-Pro-NHCH(CH3)2<br>
1.96 g Z-Val-Val-MeVal-Pro-Pro-NHCH(CH3)2 were dissolved in 11 ml methanol. 0.054 g 10 % Pd/C were added under nitrogen at¬mosphere and the reaction mixture hydrogenated at room temperature for 4 h. After addition of 0.86 ml (11.24 mmol) of a 37 % aqueous formaldehyde solution and 0.281 g 10 % Pd/C, hydrogenation was continued for 5 h. Filtration and evaporation of the solvent gave rise to 2.77 g of crude product. Further purification was achieved by dissolving the peptide in water, adjusting the pH to 2 and extracting the aqueous phase three times with ethyl acetate. The aqueous phase was then adjusted to pH 8-9 and extracted four times with dichloromethane. The organic phase was dried over sodium sulfate to yield 1.37 g of purified product as a white foam. The compound was further purified using medium pressure liq¬uid chromatography (10 - 50 % A in 10 min.; 50 - 90 % A in 320 min.). Fractions containing the product were combined, lyophilized, redissolved in water and the pH adjusted to 9 with 1 N LiOH. After extraction with dichloromethane, the organic phase was dried over sodium sulfate and evaporated to dryness. Lyophilization led to 500 mg of pure product, which was characterized by fast atom bombardment mass spectrometry 
 <br>
2 g (3.35 mmol) Z-Val-Val-MeVal-Pro-OH and 0.692 g (3.35 mmol) H-Pro-NHC(CH3)3 were dissolved in 34 ml of dry dichloro¬methane. After cooling to 0°C, 1.35 ml (12.1 mmol) N-methyl-morpholine, 0.114 g (0.84 mmol) HOBt and 0.645 g {3.35 mmol) EDCI were added and the reaction mixture stirred overnight at room temperature. 80 ml dichloromethane were added and the organic phase thoroughly washed with saturated aqueous NaHC03 solution (3x), water (lx), 5 % citric acid (3x) and saturated NaCl solution (lx). The organic phase was dried over sodium ;»    sulfate and evaporated to dryness to yield 1.8 g of the<br>
product which was used in the next reaction without further purification.<br><br>
30  Me2Val-Val-MeVal-Pro-Pro-NHC (CH3) 3<br>
1.8 g Z-Val-Val-MeVal-Pro-Pro-NHC(CH3)3 were dissolved in 10 ml methanol. 0.049 g 10 % Pd/C were added under nitrogen at¬mosphere and the reaction mixture hydrogenated at room temperature for 4 h. After addition of 0.86 ml (11.24 mmol) of a 37 % aqueous formaldehyde solution and 0.252 g 10 % Pd/C, hydrogenation was continued for 5 h. Filtration and evaporation of the solvent gave rise to 1.82 g of crude product. The compound was further purified using medium pres¬sure liquid chromatography (10 - 50 % A in 10 min.; 50 - 90 % A in 320 min.). Fractions containing the product were com¬bined, lyophilized, redissolved in water and the pH adjusted to 9 with 1 N LiOH. After extraction with dichloromethane, the organic phase was dried over sodium sulfate and evapo¬rated to dryness. Lyophilization. led to 547 tog of pure product, which was characterized by fast atom bombardment mass spectrometry ([M+H]+ = 607).<br>
The following compounds were prepared or can be prepared accord¬ing' to examples 1 and 2:<br>
3.	xaa Val Xab Pro xac<br>
4.	Xaa Val Xab Pro Xad<br>
5.	Xaa Val Xab Pro Xae<br>
6.	Xaa Val Xab Pro xaf<br>
7.	Xaa Val Xab Pro Xag<br>
8.	Xaa Val Xab Pro Xah<br>
9.	xaa Val Xab Pro Xai<br>
10.	Xaa Val Xab Pro xak<br>
11.	Xaa Val Xab Pro xal<br>
12.	Xaa val xab Pro xam<br>
13.	xaa val Xab Pro Xan<br>
14.	Xaa Val Xab Pro Xao<br>
15.	xaa val xab Pro xap<br>
16.	Xaa Val Xab Pro Xaq<br>
17.	Xaa Val Xab Pro Xar<br>
18.	xaa Val Xab Pro Xas<br>
19.	Xaa Val Xab Pro Xat<br>
r 20.	Xaa Val Xab Pro Xau<br>
21.	Xaa Val Xab Pro Xav<br>
22.	Xaa Val Xab Pro Xaw<br>
23.	Xaa Val Xab Pro Xax<br>
24.	xdd Val Xab Pro Xay<br>
i 25.	Xaa Val Xab Pro Xaz<br>
26.	Xaa Val Xab Pro Xba<br>
27.	Xaa Val Xab Pro Xbb<br><br>
28.	Xaa Val Xbc Pro Xay<br>
29.	Xaa Val Xab Pro Xbd<br>
30.	Xaa Val Xab Pro Xbe<br>
31.	Xaa Val Xab Pro Xbf<br>
32.	Xaa Val Xab Pro Xbg<br>
33.	Xaa Val Xab Pro Xbh<br>
34.	Xaa Val Xab Pro Xbi<br>
35.	Xaa Val Xab Pro Xbk<br>
36.	Xaa Val Xab Pro Xbl<br>
37.	Xaa Val Xab Pro Xbm<br>
38.	Xaa Val Xab Pro Xbn<br>
39.	Xaa Val Xab Pro Xbo<br>
40.	Xaa Val Xab Pro Xbp<br>
41.	Xaa Val Xab Pro Xbq i 42. Xaa Val Xab Pro Xbr<br><br>
43.	Xaa Val Xab Pro Xbs<br>
44.	Xaa Val Xab Pro Xbt<br>
45.	xaa Val Xab Pro xbu<br>
46.	xaa Val Xab Pro xbv<br>
47.	Xaa Val Xab Pro Xbw<br>
48.	Xaa Val Xab Pro Xbx<br>
49.	Xaa Val Xab Pro Xby<br>
50.	xaa Val Xab Pro Xbz<br>
51.	Xaa Val Xab Pro Xca<br>
52.	Xaa Val Xab Pro Xcb<br>
53.	Xaa Val Xab Pro Xcc<br>
54.	Xaa Val Xab Pro Xcd<br>
55.	Xaa Val Xab Pro Xce<br>
56.	Xaa Val Xab Pro Xcf<br>
57.	Xaa Xdf Xab Pro Xay<br>
58.	Xaa Val Xab Pro Xch<br>
59.	Xaa Val Xab Pro Xci<br>
60.	xaa Val Xab Pro Xck<br>
61.	Xaa Val Xab Pro Xcl , 62. Xaa Val Xab Pro Xcm<br><br>
63.	Xaa Val Xab Pro Xcn<br>
64.	.xaa val Xab Pro Xco<br>
65.	xaa val Xab Pro Xcp<br>
66.	Xaa Val Xab Pro Xcq<br>
67.	Xaa Val Xab Pro Xcr<br>
68.	Xaa Val Xab Pro Xcs<br>
69.	Xaa Val Xab Pro Xct<br>
70.	Xaa Val Xab Pro Xcu<br>
71.	Xcw Val Xab Pro Xcv<br>
72.	Xcx Val Xab Pro Xcv<br>
73.	Xaa Val Xab Pro Pro Xcy<br>
74.	Xaa Val Xab Pro Pro Xcz<br><br>
75.	Xaa Val Xda Pro Xcv<br>
76.	Xaa Xdb Xab Pro Xcv<br>
77.	Xde Val Xab Pro Xcv<br>
78.	Xaa lie Xab Pro Xcv f79. Xdd Val Xab Pro Xcv<br><br>
80.	Xde Val Xab Pro xcv<br>
81.	Xaa Xdf Xab Pro Xcv<br>
82.	Xaa Val Xab Pro Xcg<br>
83.	xaa Val Xab Pro Pro<br>
84.	Xaa Val Xab Pro Pro<br>
85.	Xaa Val Xab Pro Pro<br>
86.	Xaa Val Xab Pro Pro<br>
87.	Xaa Val Xdl Pro Xcv<br>
88.	Xde Val Xab Pro Xay<br>
89.	Xaa Val Xdl Pro Xay<br>
90.	Xaa Val Xab Pro Xdm<br>
91.	Xaa Val Xab Pro Xdn<br>
92.	xaa Val Xab Pro xdo<br>
93.	Xaa Val Xab Pro Xdp<br>
94.	Xaa Val Xab Pro Xdq<br>
95.	Xaa Val Xab Pro Pro<br>
96.	Xaa Val Xab Pro Xds<br>
97.	Xaa Val Xbc Pro Xcv<br>
98.	xaa lie Xab Pro Xay<br>
99.	Xcw Val Xab Pro Xay<br>
100.	Xaa Val Xbc Pro Xal<br>
101.	Xaa Val Xdl Pro Xal<br>
102.	Xaa Xdf Xab Pro Xal<br>
103.	Xaa lie Xab Pro Xal , 104. Xdd Val Xab Pro Xal<br><br>
105.	Xde Val Xab Pro Xal<br>
106.	Xcx Val Xab Pro Xcy<br>
107.	Xcw Val Xab Pro Xal<br>
108.	Xcx Val xab Pro Xal<br>
; 109. Xcw Val Xab Pro Xav<br>
110.	Xcx Val xab Pro xav<br>
111.	Xcw Val Xab Pro xaw<br>
112.	Xcx Val Xab Pro Xaw<br><br>
113.	Xab Val Xab Pro Xay<br>
114.	Xab Val Xab Pro xcv<br>
115.	Xab Val Xab Pro Xal<br>
116.	Xab Val Xab Pro Xam<br>
117.	Xab Val Xab Pro Xan<br>
118.	Xab Val Xab Pro Xao<br>
119.	Xab Val Xab Pro Xav<br>
120.	Xab Val Xab Pro Xaw<br>
121.	Xab Val Xab Pro Xat<br><br>
122.	Xab Val Xab Pro Xau<br>
123.	Xab Val Xab Pro Xbf<br>
124.	Xab Val Xab Pro Xbm<br>
125.	Xab Val Xab Pro Xbn J 126. Xab Val Xab Pro Xbo<br><br>
127.	Xab Val Xab Pro Xch<br>
128.	Xaa Val Xab Pro Xdt<br>
129.	Xaa Val Xab Pro Xdu<br>
130.	Xaa Val Xab Pro Xdv I 131. Xaa Val Xab Pro Xdw<br><br>
132.	Xaa Val Xab Pro xdx<br>
133.	Xaa Val Xab Pro Xdy<br>
134.	Xaa Val Xab Pro Xdz<br>
135.	Xaa Val Xab Pro Xea<br>
136.	Xaa Val Xab Pro Xeb<br>
137.	Xaa Val Xab Pro Xec<br>
138.	Xaa Val Xab Pro Xed<br>
139.	Xaa Val Xab Pro Xef<br>
140.	Xaa Val Xab Pro Xeg<br>
141.	xaa Val Xab Pro Xeh<br>
142.	xaa val Xab Pro Xei<br>
143.	Xaa Val Xab Pro Xek<br>
144.	Xaa Val Xab Pro Xel<br>
145.	Xaa Val Xab Pro Xem<br>
146.	Xaa Val Xab Pro Xen<br>
147.	Xaa Val Xab Pro Xeo<br>
148.	xaa val Xab Pro Xep<br>
149.	Xaa Val Xab Pro Xeq<br>
150.	Xaa val Xab Pro Xer<br>
151.	Xaa Val Xab Pro Xcg<br><br>
Examples for the MS-characterization of  the synthesized novel   " compounds are given  in the following table.<br>
EXAMPLE	Fast atom bombardment MS analy¬<br>
sis.<br>
[No.]	[Mol.-Weight  (measured)]<br>
3.	565<br>
4.	579<br>
. 5.	593<br>
6.	607<br>
7.	621<br>
8.	635<br>
■ 11.	607<br>
12.	607<br>
13.	621<br>
14.	649<br>
15.	635<br>
16.	635<br>
17.	635<br>
18.	635<br>
19.	621<br>
20.	621<br>
21.	635<br>
22.	635<br><br>
25.	633<br>
26.	647<br>
27.	661<br><br>
31.	623<br>
32.	671<br>
33.	667<br>
34.	681<br>
35.	655<br>
36.	655<br>
37.	669<br>
39.	621<br>
39.	635<br>
41.	649<br>
42.	621<br>
43.	633<br>
/  44.	667<br><br>
EXAMPLE	Fast atom bombardment MS  analy¬<br>
sis.<br>
45=	607<br>
, 46.	647<br>
47.	668<br>
48.	655<br>
49.	669<br>
50.	685<br>
51.	629<br>
52.	625<br>
53.	721<br>
55.	579<br>
58.	623<br>
61.	597<br>
62.	621<br>
63.	609<br>
64.	625<br>
65.	635<br>
66.	591<br>
67.	715<br>
68.	685<br>
69.	685<br>
70.	591<br>
71.	607<br>
72.	621<br><br>
74.	706<br>
75.	579<br>
76.	579<br>
77.	579<br>
78.	607<br>
79.	607<br>
80.	607<br>
81.	607<br>
82.	637<br>
83.	692<br>
84.	706<br>
85.	706<br>
86.	706<br>
.,      87.	607<br>
90.	635<br><br>
EXAMPLE	Fast atom bombardment MS analy-<br>
sis.<br>
92.	659<br>
. 93.	617<br>
94.	636<br>
95.	678<br>
128.	671<br>
| 131.	625<br>
139	625<br>
151.	637<br>
Table I - Sequence Identification of Compounds Prepared According<br>
to Examples 1 and 2<br>
Compound Number(s)	Sequence ID Number<br>
1-56, 58-72, 75, 77, 79, 80, 82,	1<br>
87-94, 96, 97, 99-101, 104-151<br>
) 73, 74, 83-86, 95,	2<br>
57,-76, 81, 102	3<br>
78, 98, 103	4<br>
The symbols Xaa in the summary have the following meanings:<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>
Compounds of this invention may be assayed for anti-cancer activ¬ity by conventional methods, including for example, the methods described below.<br>
A.  In vitro methodology<br>
Cytotoxicity was measured using a standard methodology for adherent cell lines such as the microculture tetrazolium assay (MTT). Details of this assay have been published (Alley, MC et al, Cancer Research 48:589-601, 1988). Exponen¬tially growing cultures of tumor cells such as the HT-29 colon carcinoma or LX-1 lung tumor are used to make micro-titer plate cultures. Cells are seeded at 3000 cells per well in 96-well plates (in 150 nl of media), and grown overnight at 37°C. Test compounds are added, in 10-fold dilutions vary¬ing from 10-4 M to 10"10 M. Cells are then incubated for 72 hours. To determine the number of viable cells in each well, the MTT dye is added (50 nl of 3 mg/ml solution of 3-(4,5-di-methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide in sa¬line) . This mixture is incubated at 37°C for 5 hours, and then 50 pi  of 25 % SDS, pH2 is added to each well. After an<br><br>
46<br>
overnight incubation, the absorbance of each well at 550 nm is read using an ELISA reader. The values for the mean +/- SD of data from replicated wells are calculated, using the for¬mula % T/C {% viable cells treated/control).<br><br>
The concentration of test compound which gives a T/C of 50% growth inhibition was designated as the IC50 value.<br>
B.  In vivo methodology<br>
Compounds of this invention were further tested in pre-clini-cal assay for in vivo activity which is indicative of clini¬cal utility. Such assays were conducted with nude mice into which tumor tissue, preferably of human origin, had been transplanted (xenografted), as is well known in this field. Test compounds were evaluated for their anti-tumor efficacy following administration to the xenograft-bearing mice.<br>
More specifically, human breast tumors (MX-1) which had been grown in athymic nude mice were transplanted into new recipi¬ent mice, using tumor fragments which were about 50 mg in size. The day of transplantation was designated as day 0. Six to ten days later, mice were treated with the test compounds given as an intravenous injection or orally, in groups of 5-10 mice at each dose. Compounds were given every other day, for 3 weeks, at doses from 1-200 mg/kg body weight.<br>
Tumor diameters and body weights were measured twice weekly. Tumor volumes were calculated using the diameters measured with Vernier calipers, and the formula<br><br>
Mean tumor volumes are calculated for each treatment group, and T/C values determined for each group relative to the un¬treated control tumors.<br>
The new compounds possess good tumor inhibiting properties.<br>
/<br><br>
tWO/4044--<br><br><br>
(B)	TYPE: amino acid<br>
(D)	TOPOLOGY: linear<br>
(ii)	MOLECULE TYPE: peptide<br>
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO: 3:<br>
Xaa Xaa Xaa Pro xaa<br>
(2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 5 amino acids<br>
(B)	TYPE: amino acid (D) TOPOLOGY: linear<br>
(ii)	MOLECULE TYPE: peptide<br>
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO: 4:<br>
Xaa He Xaa Pro Xaa<br><br><br>
We Claim:<br>
1.	A peptide of the formula I:<br>
wherein <br>
R1 is methyl;<br>
R2 is methyl;<br>
A is a valyl residue;<br>
B is a N-methyl-valyl residue;<br>
D is a prolyl residue;<br>
E is -a' prolyl residue;<br>
X is isopropyl;<br><br><br><br><br>
3.	The peptide as claimed in claim 1, in which<br>
R1 is methyl;<br>
R2 is methyl;<br>
A is'a valyl residue;<br>
B is a N-methyl-valyl residue;<br>
D is a prolyl residue;<br>
E is a prolyl residue<br>
X is isopropyl;<br>
K is NHC(CH3)3.<br>
4.	A method of preparing a peptide of formula I as claimed in claim 1 to 3,<br>
wherein the peptides are assembled sequentially from amino acids by starting<br>
at the C terminus of the peptide with R'R2N-CHX-CO and extending the chain<br>
stepwise by coupling the C terminus carbonyl with the A residue, followed by<br>
the B residue, the D residue, and the E residue, wherein the C-terminus of the<br>
E residue may  bederivatized with the K group before or after coupling;<br>
or by linking suitable small peptide fragments, wherein A, B, D, E, K, X, R1 and R2 are as defined in claim 1.<br>
5.	The method as claimed in claim 4, wherein the method comprises solution phase synthesis and utilizes an amino acid protecting group selected from the group consisting of Z, Boc and Fmoc.<br>
6.	The method as claimed in claim 5, wherein the coupling reagents are selected from the group consisting of EDCI, DCC, DIC, EEDQ, PPA, BOP-C1, PyBrop, BOP and PyBop, DPPA, HBTU, HATU, DEPCN, HOTDO, CDI, and pivaloylchloride.<br>
7.	The.method as claimed in claim 6, comprising a coupling reagent selected from the group consisting of DMAP, HOBt, HOOBt, azobenzotriazole HOSu, and 2-hydroxypyridine.<br><br>
8.	The method as claimed in claim 5, wherein the method comprises solution phase synthesis and utilizes a Z amino acid protecting group, EDCI and HOBt as the coupling reagents, and the compound is deprotected using Pd/C under a nitrogen atmosphere.<br>
9.	The method as claimed in claim 8, wherein the method comprises solid phase synthesis and utilizes an amino acid protecting group selected from the group consisting of Z, Boc, and Fmoc.<br>
10.	The method as claimed in claim 9, wherein the coupling reagents are selected from the group consisting of EDCI, DCC, DIC, EEDQ, PPA, BOP-C1, PyBrop, BOP and PyBop, DPPA,  HBTU, HATU, DEPCN, HOTDO, CDI, and<br>
pivaloylchloride.<br>
11.	A medicament comprising a peptide of formula I as claimed in claim 1 or<br>
a pharmaceutically acceptable salt thereof.<br><br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjI0MC1tYXMtMTk5NiBhYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">2240-mas-1996 abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjI0MC1tYXMtMTk5NiBhc3NpZ25tZW50LnBkZg==" target="_blank" style="word-wrap:break-word;">2240-mas-1996 assignment.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjI0MC1tYXMtMTk5NiBjbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">2240-mas-1996 claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjI0MC1tYXMtMTk5NiBjb3JyZXNwb25kZW5jZS1vdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">2240-mas-1996 correspondence-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjI0MC1tYXMtMTk5NiBjb3JyZXNwb25kZW5jZS1wby5wZGY=" target="_blank" style="word-wrap:break-word;">2240-mas-1996 correspondence-po.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjI0MC1tYXMtMTk5NiBkZXNjcmlwdGlvbihjb21wbGV0ZSkucGRm" target="_blank" style="word-wrap:break-word;">2240-mas-1996 description(complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjI0MC1tYXMtMTk5NiBmb3JtLTEucGRm" target="_blank" style="word-wrap:break-word;">2240-mas-1996 form-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjI0MC1tYXMtMTk5NiBmb3JtLTE5LnBkZg==" target="_blank" style="word-wrap:break-word;">2240-mas-1996 form-19.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjI0MC1tYXMtMTk5NiBmb3JtLTIucGRm" target="_blank" style="word-wrap:break-word;">2240-mas-1996 form-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjI0MC1tYXMtMTk5NiBmb3JtLTI2LnBkZg==" target="_blank" style="word-wrap:break-word;">2240-mas-1996 form-26.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjI0MC1tYXMtMTk5NiBmb3JtLTQucGRm" target="_blank" style="word-wrap:break-word;">2240-mas-1996 form-4.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjI0MC1tYXMtMTk5NiBmb3JtLTYucGRm" target="_blank" style="word-wrap:break-word;">2240-mas-1996 form-6.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjI0MC1tYXMtMTk5NiBvdGhlci5wZGY=" target="_blank" style="word-wrap:break-word;">2240-mas-1996 other.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjI0MC1tYXMtMTk5NiBvdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">2240-mas-1996 others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjI0MC1tYXMtMTk5NiBwZXRpdGlvbi5wZGY=" target="_blank" style="word-wrap:break-word;">2240-mas-1996 petition.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="235117-heterocyclic-aspartyl-protease-inhibitors.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="235119-a-batch-mixer.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>235118</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>2240/MAS/1996</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>29/2009</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>17-Jul-2009</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>25-Jun-2009</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>11-Dec-1996</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>ABBOTT GMBH &amp; CO. KG</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>MAX-PLANCK-RING 2, 65205 WIESBADE</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>WILHELM AMBERG</td>
											<td>STETTINER RING 24,61381 FRIEDRICHSDORF</td>
										</tr>
										<tr>
											<td>2</td>
											<td>TERESA BARLOZZARRI</td>
											<td>24 SOUTH WOODSIDE AVE, WELLESLEY, MA 02181.</td>
										</tr>
										<tr>
											<td>3</td>
											<td>HARALD BERNARD</td>
											<td>VALENTIN-OSTERTAG-STR.2,67098 BAD DURKHEIM.</td>
										</tr>
										<tr>
											<td>4</td>
											<td>ERNST BUSCHMANN</td>
											<td>GEORG-LUDWIG-KREBS-STR310, 67069 LUDWIGSHAFEN.</td>
										</tr>
										<tr>
											<td>5</td>
											<td>ANDREAS HAUPT</td>
											<td>2 ROSEWOOD PLACE, WESTBOROUGH, MA 01581.</td>
										</tr>
										<tr>
											<td>6</td>
											<td>HANS-GUENTHER HEGE</td>
											<td>DINKELACKERRING 29,67435 NEUSTADT.</td>
										</tr>
										<tr>
											<td>7</td>
											<td>BERNRD JANSSEN</td>
											<td>LEUSCHNERSTR, 18A, 67063 LUDWIGSHAFEN, FEDERAL REPUBLIC OF GEMANY</td>
										</tr>
										<tr>
											<td>8</td>
											<td>ANDREAS KLING</td>
											<td>RIEGELER WEG 14,68239 MANNHEIM</td>
										</tr>
										<tr>
											<td>9</td>
											<td>HELMUT LIETZ</td>
											<td>RAIFFEISENSTR, 15,67435 NEUSTADT.</td>
										</tr>
										<tr>
											<td>10</td>
											<td>KURT RITTER</td>
											<td>9 BURTON AVENUE, NEWTON, MA022158</td>
										</tr>
										<tr>
											<td>11</td>
											<td>MARTINA ULLRICH</td>
											<td>IM RAPPENBUCKELWEG 16,69198 SCHRIESHEIM.</td>
										</tr>
										<tr>
											<td>12</td>
											<td>JURGEN WEYMANN</td>
											<td>SEEBACHER STR.23,67098 BAD DURKHEIM.</td>
										</tr>
										<tr>
											<td>13</td>
											<td>THOMAS ZIERKE</td>
											<td>AKAZIENSTR.12, 67459 BOHL-IGGELHEIM</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07K7/06</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>N/A</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td></td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>08/573,422</td>
									<td>1995-12-15</td>
								    <td>U.S.A.</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/235118-novel-peptides-the-preparation-and-a-medicament-comprising-the-same by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 14:37:15 GMT -->
</html>
